Risk-Benefit Assessment of Omeprazole in the Treatment of Gastrointestinal Disorders
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 10 (1), 66-82
- https://doi.org/10.2165/00002018-199410010-00005
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Omeprazole-induced hypergastrinemia does not influence growth of colon carcinomaDigestive Diseases and Sciences, 1992
- Gastrin and colorectal cancerDigestive Diseases and Sciences, 1992
- Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazoleDigestive Diseases and Sciences, 1991
- Omeprazole Drug Interaction StudiesClinical Pharmacokinetics, 1991
- Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomachMutation Research, 1991
- Long-term maintenance treatment of reflux esophagitis with omeprazoleDigestive Diseases and Sciences, 1991
- Antisecretory therapy and genotoxicityDigestive Diseases and Sciences, 1991
- Clinical Pharmacology of OmeprazoleClinical Pharmacokinetics, 1991
- Effect of Omeprazole and Ranitidine on Ulcer Healing and Relapse Rates in Patients with Benign Gastric UlcerNew England Journal of Medicine, 1989
- Irreversible inactivation of rat gastric (H+-K+)-ATPase invivo by omeprazoleBiochemical and Biophysical Research Communications, 1985